Manufactured by:TriBio Science
RUO

IPI-549, Selective PI3Kγ

IPI-549 is a potent and highly selective inhibitor of PI3K-γ in both biochemical (IC50 = 16 nM) and cellular (IC50 = 12.2 nM) assays. Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression. IPI-549 has been used to reshape tumor immune...

SKU:
ABM147191-1
Manufacturer SKU
TBI4827-25MG | TBI4827-5MG
Product type
Biochemical Inhibitors
TargetPI3Kγ
Purity>98%

Manufacturer provenance

Manufactured by:
TriBio Science
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

IPI-549 is a potent and highly selective inhibitor of PI3K-γ in both biochemical (IC50 = 16 nM) and cellular (IC50 = 12.2 nM) assays. Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression. IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3K-γ inhibition via IPI-549. IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines. IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance

Key facts & specifications
Also known as
(S)-2-Amino-N-[1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
Molecular weight
629.68
Form / buffer
powder
Activity
IPI-549 is a potent and highly selective inhibitor of PI3K-γ in both biochemical (IC50 = 16 nM) and cellular (IC50 = 12.2 nM) assays. Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression. IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3K-γ inhibition via IPI-549. IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines. IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance.
Molecular formula
C 30 H 24 N 8 O 2
Solubility
Soluble in DMSO (up to at least 25 mg/ml)
Technical note
Stability: ≥ 1 year.
Identifiers & database references
Manufacturer SKU
TBI4827-25MG | TBI4827-5MG
CAS number
1693758-51-8
Storage, stability & shipping
Storage conditions
-20°C
Shipped at
4°C
Long-term storage
-20°C
Compliance & documents
Datasheet
Open datasheet
Safety data sheet
Open SDS
Frequently asked questions
Who manufactured this product?

This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

TriBio Science
£286.00